James P Callahan

US Patent:

6492425, Dec 10, 2002

Filed:

Dec 19, 2000

Appl. No.:

09/720018

Inventors:

James F. Callahan - Philadelphia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31165

US Classification:

514622

Abstract:

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF- B, and methods for treating diseases in which activation of NF- B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF- B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimers disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

US Patent:

6825188, Nov 30, 2004

Filed:

Oct 22, 2003

Appl. No.:

10/691241

Inventors:

James Francis Callahan - Philadelphia PA
Russell Donovan Cousins - Oxford PA
Richard McCulloch Keenan - Malvern PA
Chet Kwon - King of Prussia PA
William Henry Miller - Schwenksville PA
Irene Nijole Uzinskas - Villanova PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 3144

US Classification:

51421207, 540531

Abstract:

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.

US Patent:

20030092771, May 15, 2003

Filed:

Jul 31, 2002

Appl. No.:

10/210560

Inventors:

James Callahan - Philadelphia PA, US

Assignee:

SmithKline Beecham Corporation

International Classification:

A61K031/165

US Classification:

514/617000, 514/619000, 514/622000

Abstract:

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF- B, and methods for treating diseases in which activation of NF- B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF- B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

US Patent:

20030125317, Jul 3, 2003

Filed:

Dec 16, 2002

Appl. No.:

10/320084

Inventors:

James Callahan - Philadelphia PA, US
Russell Cousins - Oxford PA, US
Richard Keenan - Malvern PA, US
Chet Kwon - King of Prussia PA, US
William Miller - Schwenksville PA, US
Irene Uzinskas - Villanova PA, US

Assignee:

SmithKline Beecham Corporation

International Classification:

A61K031/55
C 07D 4 3/02

US Classification:

514/212070, 540/523000

Abstract:

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.

US Patent:

20040039198, Feb 26, 2004

Filed:

May 14, 2003

Appl. No.:

10/416761

Inventors:

Paul Bender - Cherry Hill NJ, US
Joelle Burgess - Collegeville PA, US
James Callahan - Collegeville PA, US

International Classification:

C07D417/14
C07D413/14
C 07D 4 3/14

US Classification:

544/049000, 544/105000, 544/284000, 544/353000, 546/272700

Abstract:

This invention relates to 2-pyridyl substituted diarylimidazoles which are inhibitors of the transforming growth factor, (“TGF”)- signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine.

US Patent:

20060035979, Feb 16, 2006

Filed:

Oct 3, 2005

Appl. No.:

11/242572

Inventors:

James Callahan - Philadelphia PA, US

International Classification:

A61K 31/165

US Classification:

514622000

Abstract:

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

US Patent:

45433496, Sep 24, 1985

Filed:

Aug 28, 1984

Appl. No.:

6/645127

Inventors:

James F. Callahan - Philadelphia PA
Michael L. Moore - Media PA
Nelson C. Yim - Ambler PA

Assignee:

SmithKline Beckman Corporation - Philadelphia PA

International Classification:

A61K 3700
C07C10352

US Classification:

514 11

Abstract:

Certain cyclic vasopressin-like peptides, which have an. omega. -amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have vasopressin antagonist activity. A species of this series of new compounds is [1-(. beta. -mercapto-. beta. ,. beta. -cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desarginine -9-desglycinamide]-vasopressin.

US Patent:

54381185, Aug 1, 1995

Filed:

Jul 26, 1993

Appl. No.:

8/066136

Inventors:

James F. Callahan - Philadelphia PA
William F. Huffman - Malvern PA
Michael L. Moore - Media PA
Kenneth A. Newlander - West Chester PA

Assignee:

SmithKline Beechman Corp. - Philadelphia PA

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

530330

Abstract:

Peptide mimics, having a constrained peptide backbone conformation, are HIV protease inhibitors. A compound of this invention is, for example, 3-Benzyl-5(alaninyl-1-aminoethyl)-2,3,6,7-tetrahydro-N-azepinyl-2-propiony l-valinyl-valinyl methyl ester.

Author:

James Morton Callahan

ISBN #:

0384071953

Author:

James Patrick Callahan

ISBN #:

0810831260

Author:

James Patrick Callahan

ISBN #:

0830815848

Author:

James Callahan

ISBN #:

0686332571

Author:

James Callahan

ISBN #:

0716726300

Author:

James Callahan

ISBN #:

0815400446

Author:

James M. Callahan

ISBN #:

0071470204

Author:

James M. Callahan

ISBN #:

0404013643